IBB logo

iShares Trust - iShares Biotechnology ETF Stock Price

NasdaqGM:IBB Community·US$8.9b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author

IBB Share Price Performance

US$187.36
60.85 (48.10%)
US$187.36
60.85 (48.10%)
Price US$187.36

IBB Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Excellent balance sheet with questionable track record.

2 Risks
2 Rewards

iShares Trust - iShares Biotechnology ETF Key Details

US$41.6m

Revenue

US$0

Cost of Revenue

US$41.6m

Gross Profit

-US$1.7b

Other Expenses

US$1.7b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
35.87
100.00%
4,098.77%
9.3%
View Full Analysis

About IBB

Founded
2001
Employees
n/a
CEO
n/a
WebsiteView website
www.ishares.com/us/products/239699/ishares-nasdaq-biotechnology-etf

iShares Trust - iShares Biotechnology ETF is an exchange traded fund launched by BlackRock, Inc. It is managed by BlackRock Fund Advisors. It invests in public equity markets of the United States. It invests in stocks of companies operating across biotechnology sectors. It invests in growth and value stocks of companies across diversified market capitalization. The fund seeks to track the performance of the NYSE Biotechnology Index, by using representative sampling technique. iShares Trust - iShares Biotechnology ETF was formed on February 5, 2001 and is domiciled in the United States.

Recent IBB News & Updates

Seeking Alpha Apr 02

Biotech Is Holding Steady In 2026

Summary The biotech sector, tracked by the iShares Biotechnology ETF (IBB), remained flat in early 2026, despite broader market declines and volatility. Recent high buyout premium M&A activity, including Biogen’s $5.6B Apellis acquisition, fueled sector outperformance and an uptick in investor enthusiasm. Rotation out of the Magnificent Seven and into value sectors provided marginal support for biotech’s relative strength in 1Q2026. Energy, Consumer Defensive, and Utilities led S&P 500 sector gains, but biotech outperformed the broader indexes in Q1. An assessment of the biotech sector through the first quarter of 2026 follows in the paragraphs below. Read the full article on Seeking Alpha

Recent updates

No updates